Igyxos S.A. has completed a Series A fundraising
Igyxos S.A. has completed a US$8.4 million fundraising as part of a Series A funding led by Bpifrance through its FABS Fund, with participation from the Go Capital Amorçage II and Loire Valley Invest Funds and by the Emergence Innovation II. This will allow the founder Marie Christine Maurel and Professor René Frydman, joined by Pierre-Henry Longeray (ex Merck Serono) as CEO, to pursue the proof of concept in human clinical practice.
Based in Nouzilly, France, biotechnology startup Igyxos is developing a new treatment for female and male infertility that works by shifting hormonal imbalances with a new method using monoclonal antibodies.
Oaklins’ team in France advised Igyxos on a "dual-track" project that allowed them to validate with the industry both scientific and therapeutic interest of its drug candidate based on the use of monoclonal antibodies to improve the treatment of female and male infertility.
![](/api/deal-hero-image/105045/deal-hero-image.jpg)
![](/api/deal-party-images/105045/deal-parties.png)
![](/api/deal-client-photo/105045/deal-client-photo.jpg)
Marie-Christine Maurel
CSO and Founder, Igyxos, S.A.
Talk to the deal team
Related deals
Royal Reesink has sold Motrac Industries to Anders Invest
Royal Reesink and Anders Invest have completed the sale of Motrac Industries, a specialist in hydraulic and electrical engineering.
Learn moreÑaming, SL has been acquired by DeA Capital S.p.A.
Spain’s leading producer of sandwiches, fresh and ultra-fresh products, Ñaming, has sold a majority stake to Italian fund DeA Capital.
Learn moreUniKidz has partnered with Karmijn Kapitaal
Karmijn Kapitaal has acquired a majority stake in UniKidz, a talent development organization that provides a scientifically-based developmental approach through high-quality childcare. Through the partnership with Karmijn Kapitaal, UniKidz can take the next step in bringing their unique concept to even more children.
Learn more